Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4+ T cell function

Mesenchymal stem cells (MSCs) have recently emerged as promising candidates for cell-based immune tolerance therapy. Interleukin 35 (IL-35) is a relatively newly identified cytokine required for the regulatory and suppressive functions of regulatory T cells (Treg), playing an important role in the prevention of autoimmune diseases. In this study, we isolated adipose tissue-derived MSCs, a good vehicle for cell therapy, which were transfected with a lentivirus vector for the overexpression of the therapeutic murine IL-35 gene. IL-35 levels in transfected MSCs (IL-35-MSCs) were quantified by ELISA. Co-culture of CD4(+) T cells and IL-35-MSCs resulted in the inhibition of CD4(+) T cell proliferation and IL-17A secretion. In addition, IL-35-MSCs induced IL-10 production by CD4(+) T cells, but did not affect IFN-gamma. These findings suggested that MSCs over-expressing IL-35 had higher immunosuppressive capacity compared with non-transfected MSCs, and may provide a useful approach for basic research on gene therapy for autoimmune disorders.(C) 2016 Elsevier Inc. All rights reserved.